Bob Jackson

Roche Ltd. provides investment services.

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York.

FSC Laboratories, Inc. engages in development of prescription medicines and medical devices. The company was founded by Peter W. Steelman in April 16, 2004 and is headquartered in Charlotte, NC.

Avadel Pediatrics, Inc. markets and distributes pediatric pharmaceutical products and medical devices. It offers AcipHex Sprinkle, Cefaclor for Oral Suspension, Flexichamber and Karbinal ER products. The company was founded by Peter W. Steelman in 2004 and is headquartered in Charlotte, NC.

Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom.

Convelo Therapeutics, Inc. develops medicines that unlock the regenerative capacity of the central nervous system. The company was founded by Paul Tesar and Drew Adams in 2016 and is headquartered in Cleveland, OH.

Ophirex, Inc. develops antidotes to snakebite. The company was founded by Jerry D. Harrison and Matthew Lewin and is headquartered in Corte Madera, CA.

Cystetic Medicines, Inc. is a clinical-stage biotechnology company located in Champaign, IL. The company is pioneering the development of small molecule anion channel prosthetics to restore protein function in people with cystic fibrosis (CF). The company utilizes a proprietary inhaled dry powder formulation that enables improved dose consistency and high efficiency delivery to the airways. Currently, they are focused on the development of CM001, a novel inhalable small molecule therapeutic designed to restore ion balance and host defenses in the lungs to treat CF. The company was founded in 2020 based on the work of Dr. Martin Burke of the University of Illinois at Urbana-Champaign and Dr. Michael Welsh at the University of Iowa.